Fenfluramine disrupts the mitral valve interstitial cell response to serotonin.
Serotonin (5HT) receptor signaling and 5HT-related agents, such as the anorexogen fenfluramine (Fen), have been associated with heart valve disease. We investigated the hypothesis that Fen may disrupt mitral valve interstitial cell (MVIC) homeostasis through its effects on mitogenesis and extracellular matrix biosynthesis. Normal and myxomatous mitral valves, both human and canine, were harvested, and primary MVIC cultures were established. 5HT caused increased phosphorylation of extracellular signal-related kinase in MVIC; Fen alone did not. However, Fen combined with 5HT increased the level of MVIC extracellular signal-related kinase, when compared with 5HT alone. In addition, MVIC mitogenesis per (3)H-thymidine ((3)HTdR) demonstrated a 5HT dose-dependent increase, with no effect of Fen alone. In contrast, Fen combined with 5HT inhibited the MVIC (3)HTdR response when compared with 5HT alone. Furthermore, fluoxetine, a 5HT transporter inhibitor, while having no effect alone, suppressed Fen-5HT (3)HTdR inhibition when administered with Fen plus 5HT. Finally, MVIC incorporations of (3)H-proline and (3)H-glucosamine, measures of extracellular matrix collagen and glycosaminoglycan respectively, were increased with 5HT alone; however, Fen did not affect MVIC glycosaminoglycan or collagen either alone or in combination with 5HT. Taken together, the ratios of (3)H-proline or (3)H-glycosaminoglycan to (3)HTdR in MVIC, normalized to 5HT alone, demonstrated a significant imbalance of extracellular matrix production versus proliferation in MVIC cultures with Fen plus 5HT exposure. This imbalance may explain in part the pathophysiology of Fen-related mitral valve disease.
Connolly
Jeanne M
JM
Division of Cardiology, The Children's Hospital of Philadelphia, 3615 Civic Center Boulevard, Philadelphia, PA 19104-4318, USA. connolly@email.chop.edu
Bakay
Marina A
MA
Fulmer
James T
JT
Gorman
Robert C
RC
Gorman
Joseph H
JH
Oyama
Mark A
MA
Levy
Robert J
RJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004336:Drug Antagonism; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis; D005260:Female; D005277:Fenfluramine / Q000494:pharmacology*; D006349:Heart Valve Diseases; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000187:drug effects* / Q000473:pathology; D011985:Receptors, Serotonin / Q000378:metabolism; D012701:Serotonin / Q000494:pharmacology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D055815:Young Adult
D016326:Extracellular Matrix Proteins; D005277:Fenfluramine; D011985:Receptors, Serotonin; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors
Neuropsychopharmacology. 2004 Oct;29(10):1790-9
15226739
Trends Pharmacol Sci. 1999 Dec;20(12):490-5
10603491
Pharmacol Biochem Behav. 2002 Apr;71(4):825-36
11888573
Circulation. 1999 Nov 23;100(21):2161-7
10571975
Neuropharmacology. 1999 Aug;38(8):1083-152
10462127
Am J Pathol. 2002 Dec;161(6):2209-18
12466135
J Appl Physiol (1985). 2002 Nov;93(5):1770-8
12381765
Mol Pharmacol. 2003 Jun;63(6):1223-9
12761331
Ann N Y Acad Sci. 2000 Sep;914:172-86
11085319
Am J Pathol. 2002 Dec;161(6):2111-21
12466127
Cardiovasc Pathol. 2002 Sep-Oct;11(5):251-62
12361835
Science. 1996 Nov 29;274(5292):1527-31
8929413
Anal Biochem. 2000 Oct 15;285(2):211-9
11017704
Am J Cardiol. 2000 Apr 1;85(7):913-5, A10
10758942
Arch Neurol. 2007 Mar;64(3):377-80
17353380
N Engl J Med. 1998 Sep 10;339(11):719-24
9731087
Eur J Pharmacol. 2006 Nov 21;550(1-3):149-54
17026993
J Heart Valve Dis. 2002 May;11(3):308-14; discussion 314
12056720
J Pharmacol Exp Ther. 2008 Feb;324(2):791-7
18032571
Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):377-87
16863450
Mol Psychiatry. 2000 Jul;5(4):357-62
10889545
N Engl J Med. 2007 Jan 4;356(1):6-9
17202450
Circulation. 2000 Dec 5;102(23):2836-41
11104741
N Engl J Med. 2007 Jan 4;356(1):39-46
17202454
J Surg Res. 2005 Jun 1;126(1):102-5
15916982
J Heart Valve Dis. 2008 Jul;17(4):402-11; discussion 412
18751470
N Engl J Med. 1997 Aug 28;337(9):581-8
9271479
Regul Pept. 2007 Oct 4;143(1-3):39-46
17391782
Circulation. 2006 Jan 3;113(1):81-9
16380550
Circulation. 2001 Nov 20;104(21):2525-32
11714645
Pharmacol Biochem Behav. 2002 Apr;71(4):533-54
11888546
Mol Pharmacol. 2000 Jan;57(1):75-81
10617681
Biochem Soc Trans. 1991 Feb;19(1):95-8
2037207
N Engl J Med. 2003 Mar 13;348(11):1005-15
12637610
Circulation. 2005 Mar 29;111(12):1517-22
15781732
Arch Pathol Lab Med. 2001 Dec;125(12):1555-61
11735689
Lancet. 1996 May 11;347(9011):1340-1
8622543
Curr Opin Drug Discov Devel. 2006 Jan;9(1):38-46
16445116
Methods Enzymol. 1992;215:213-24
1435323
Ann N Y Acad Sci. 1990;600:53-66; discussion 67
2252332
Am J Cardiol. 2001 Apr 15;87(8):989-93: A4
11305992
Mol Pharmacol. 2005 Jul;68(1):20-33
15831837
Cardiovasc Res. 2000 Aug;47(2):234-43
10946060